FDA Pediatric Incentives, Powers Would Become Permanent Under Draft Bill
Executive Summary
In the absence of sunset provisions that necessitate periodic reauthorization of the pediatric laws, GAO would report to Congress on a five-year cycle about the accomplishments of the drug programs for children and make recommendations for amendments.
You may also be interested in...
Pediatric Study Plans Would Be Required At End Of Phase II Under Bipartisan House Bill
Rather than assessing monetary penalties for violating study deadlines, H.R. 4274 directs FDA to issue warning letters and publish them on its website.
User Fee Package Offers FDA Reforms From A House Wary Of FDA Power
House drafters’ dissatisfaction with FDA’s performance is evident in several provisions of draft user fee legislation. The agency would be required to finalize some guidances within a year of issuing a draft, which likely would provide more predictability for industry.
User Fee Package Offers FDA Reforms From A House Wary Of FDA Power
House drafters’ dissatisfaction with FDA’s performance is evident in several provisions of draft user fee legislation. The agency would be required to finalize some guidances within a year of issuing a draft, which likely would provide more predictability for industry.